jRCT2080221672未知3 期
Phase3 study of T-1220 in the patients with bacterial infectious disease-Open label, multi-center study-
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点开始时间: 待定
试验速览
- 阶段
- 3 期
- 发起方
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open label, multi-center study
入排标准
- 年龄范围
- 20age old over 至 15age old under（—）
- 性别
- All
入选标准
- •(1)Sex:male or female
- •(2)Age: 20 years and older for adult and 28 days to 16 years old (inclusive) for child
- •(3)Outpatient or inpatient: inpatient
- •(4)Presence of definite symptom/findings of infectious disease
排除标准
- •(1)Medical history of allergy to any beta-lactam antibacterial agents.
- •(2)Patient with infectious mononucleosis.
- •(3)Pregnant females, females wishing to become pregnant or being possibly pregnant, and lactating females.
结局指标
主要结局
-
Efficacy and safety Same as above
次要结局
未报告次要终点
研究者
相似试验
未知
3 期
Phase3 study of T-1220 in the patients with bacterial infectious disease-Open label, multi-center studySepsis, Acute bronchitis, Pneumonia, Lung abscess, Pyothorax, Secondarinfection of chronic respiratory disease, Cystitis, Pyelonephritis, Cholecystitis, Cholangitis, Bartholinitis, Intrauterine infection, Uterine adnexitis, Parametritis, Purulent meningitisyJPRN-jRCT2080221672Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
已完成
3 期
Phase III clinical study of TY-0201 in patients with chronic atrial fibrillation -Confirmatory Study-jRCT2080222737TOA EIYO LTD.188
已完成
3 期
Phase III clinical study of TY-0201 in patients with chronic atrial fibrillation -long-term study-jRCT2080222649TOA EIYO LTD.100
已完成
3 期
Phase III study of FTB-8127 in patients with post-herpetic neuralgia (A placebo-controlled, multicenter, double-blind, parallel-group study)Post-herpetic neuralgiaJPRN-jRCT2080220444FUSO Pharmaceutical Industries, Ltd.135
未知
3 期
A phase III study of TAC-202 in patients with perennial allergic rhinitisjRCT2080222549Taiho Pharmaceutical Co., Ltd.750